Baseline characteristics of aCML and CNL patients identified in the NCDB
| Characteristic . | aCML, N = 702 . | CNL, N = 294 . | P value . |
|---|---|---|---|
| Age, y median (IQR) | 72 (62, 80) | 71 (64, 79) | .5 |
| Sex, N (%) | .5 | ||
| Female | 267 (38.0%) | 118 (40.1%) | |
| Male | 435 (62.0%) | 176 (59.9%) | |
| Race, N (%) | .4 | ||
| Black | 63 (9.0%) | 21 (7.1%) | |
| White | 599 (85.3%) | 254 (86.4%) | |
| Other | 40 (5.7%) | 19 (6.5%) | |
| JAK2 mutated, N (%)∗ | 29 (13.8%) | 16 (15.3%) | .10 |
| CCI, N (%) | .4 | ||
| 0 | 509 (72.5%) | 220 (74.8%) | |
| 1 | 107 (15.2%) | 44 (15.0%) | |
| 2 | 47 (6.7%) | 21 (7.1%) | |
| ≥3 | 39 (5.6%) | 9 (3.1%) | |
| Unknown | 7 (1.0%) | 1 (0.3%) | |
| Year of diagnosis, N (%) | .8 | ||
| 2004-2008 | 106 (15.1%) | 47 (16.0%) | |
| 2009-2013 | 182 (25.9%) | 78 (26.5%) | |
| 2014-2018 | 286 (40.7%) | 110 (37.4%) | |
| 2019-2020 | 128 (18.2%) | 59 (20.1%) |
| Characteristic . | aCML, N = 702 . | CNL, N = 294 . | P value . |
|---|---|---|---|
| Age, y median (IQR) | 72 (62, 80) | 71 (64, 79) | .5 |
| Sex, N (%) | .5 | ||
| Female | 267 (38.0%) | 118 (40.1%) | |
| Male | 435 (62.0%) | 176 (59.9%) | |
| Race, N (%) | .4 | ||
| Black | 63 (9.0%) | 21 (7.1%) | |
| White | 599 (85.3%) | 254 (86.4%) | |
| Other | 40 (5.7%) | 19 (6.5%) | |
| JAK2 mutated, N (%)∗ | 29 (13.8%) | 16 (15.3%) | .10 |
| CCI, N (%) | .4 | ||
| 0 | 509 (72.5%) | 220 (74.8%) | |
| 1 | 107 (15.2%) | 44 (15.0%) | |
| 2 | 47 (6.7%) | 21 (7.1%) | |
| ≥3 | 39 (5.6%) | 9 (3.1%) | |
| Unknown | 7 (1.0%) | 1 (0.3%) | |
| Year of diagnosis, N (%) | .8 | ||
| 2004-2008 | 106 (15.1%) | 47 (16.0%) | |
| 2009-2013 | 182 (25.9%) | 78 (26.5%) | |
| 2014-2018 | 286 (40.7%) | 110 (37.4%) | |
| 2019-2020 | 128 (18.2%) | 59 (20.1%) |
CCI, Charlson Comorbidity Index; IQR, interquartile range.
JAK2 results were available for 222 aCML and 104 CNL cases.